tremelimumab (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Hepatocellular Carcinoma

Pending FDA approval for a single immune priming dose in patients with unresectable hepatocellular carcinoma (HCC) before administering durvalumab

Next:

Pharmacology

Mechanism of Action

Human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on activated T-lymphocytes; this prevents binding of antigen-presenting cell ligands B7-1 (CD80) and B7-2 (CD86) to CTLA-4

CTLA-4-mediated down-regulation of T-cell activity is therefore blocked; this allows B7-1 and B7-2 to bind with CD28 (a co-stimulatory T-cell protein) resulting in activation of T-cells and priming the immune response to cancer cells

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.